A Study of KC1036 in Patients with Advanced Thymic Tumors

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 22, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2026

Conditions

Thymic Tumors

Interventions

DRUG

KC1036

Patients take 60mg QD of KC1036 for the efficacy and safety study. KC1036 are given orally once daily, 21 days as a cycle.

Trial Locations (2)

RECRUITING

Shanghai Chest Hospital, Shanghai

RECRUITING

West China Hospital, Chengdu

All Listed Sponsors

lead

Beijing Konruns Pharmaceutical Co., Ltd.

INDUSTRY

NCT05683886 - A Study of KC1036 in Patients with Advanced Thymic Tumors | Biotech Hunter | Biotech Hunter